Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
Biohaven presented preclinical data for BHV-1420, its second TRAP degrader, at ASN Kidney Week 2026, targeting the anti-PLA2R autoantibodies that drive membranous nephropathy. In a clinical diagnostic ELISA, BHV-1420 brought 88% of anti-PLA2R-positive patient samples (n=59) below the positivity threshold, and in mice a single subcutaneous dose depleted >90% of circulating autoantibody within two hours, sustained for 72 hours. BHV-1420 joins BHV-1400 in IgA nephropathy in the Yale-licensed nephrology franchise; BHV-1400 has shown ~70% Gd-IgA1 reduction in a Phase 1b IgAN study.
Key figures
- Drug Name
- BHV-1420
- Phase Of Trial
- Preclinical
- Top dose tested
- 4.8 mg/kg subcutaneous
- Mouse antibody depletion
- >90% within two hours, sustained over 72 hours
- Elisa samples below positivity threshold
- 88% of anti-PLA2R-positive samples (n=59)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.